<DOC>
	<DOCNO>NCT00235937</DOCNO>
	<brief_summary>The purpose study determine efficacy tolerance association two drug already market used treat disease : Arimidex® 1 Mg per day per o Zoladex® 3,6 Mg injection cutaneous per month subject breast cancer .</brief_summary>
	<brief_title>Study Pre-menopausal Patients With Advanced ER PR + BC Treated With Arimidex Plus Zoladex</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Signed informed consent , premenopausal woman 18 year old , histologically cytologically confirm locally advanced metastatic breast cancer , suitable endocrine treatment , curative treatment available , , one measurable lesion , life expectancy 6 month , normal biological parameter . Presence lifethreatening metastasis , previous endocrine therapy chemotherapy advance metastatic disease , previous treatment hormone ( LHRH ) severe uncontrolled systemic disease , pituitary adenoma , High risk medullar compression .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Premenopausal</keyword>
	<keyword>Advanced Breast Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>